Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis

HONG KONG, March 11, 2026 - (ACN Newswire via SeaPRwire.com) – March 9, Everest Medicines (1952.HK) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated Hospital of Sun Yat-sen University, marking a milestone in patient access…

MarketingPulse and eTailingPulse open next Thursday

HONG KONG, Mar 11, 2026 - (ACN Newswire via SeaPRwire.com) – Organised by the Hong Kong Trade Development Council (HKTDC), MarketingPulse and eTailingPulse – Asia’s premier annual e-commerce and marketing events – will be held concurrently on 19 March at the Hong Kong Convention and Exhibition Centre (HKCEC). Under the theme "Generate New Growth",…

Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting

TOKYO, Mar 11, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai’s anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease (AD), at…